Faculty Opinions recommendation of Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma.

Previously Treated

A phase I dose escalation trial of PT2385, a first-in-class oral HIF-2a inhibitor, in patients with advanced clear cell renal cell carcinoma.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.2506 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 2506-2506 ◽

Cited By ~ 4

Author(s):

Kevin Dale Courtney ◽

Jeffrey R. Infante ◽

Elaine Tat Lam ◽

Robert A. Figlin ◽

Brian I. Rini ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Phase I ◽

Cell Carcinoma ◽

Dose Escalation ◽

Renal Cell ◽

Clear Cell ◽

Prognostic significance of hypoxia inducible factor-1α expression in patients with clear cell renal cell carcinoma

Molecular Medicine Reports ◽

10.3892/mmr.2018.8409 ◽

2018 ◽

Cited By ~ 2

Author(s):

Shuiqing Wu ◽

Fen Jiang ◽

Hongtao Wu ◽

Yinhuai Wang ◽

Ran Xu ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Clear Cell ◽

Prognostic Significance ◽

Hypoxia Inducible Factor 1Α

Sunitinib Dose Escalation Overcomes Transient Resistance in Clear Cell Renal Cell Carcinoma and Is Associated with Epigenetic Modifications

Molecular Cancer Therapeutics ◽

10.1158/1535-7163.mct-14-0208 ◽

2014 ◽

Vol 14 (2) ◽

pp. 513-522 ◽

Cited By ~ 42

Author(s):

Remi Adelaiye ◽

Eric Ciamporcero ◽

Kiersten Marie Miles ◽

Paula Sotomayor ◽

Jonathan Bard ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Dose Escalation ◽

Renal Cell ◽

Clear Cell ◽

Epigenetic Modifications ◽

Poor prognosis and advanced clinicopathological features of clear cell renal cell carcinoma (ccRCC) are associated with cytoplasmic subcellular localisation of Hypoxia inducible factor-2α

European Journal of Cancer ◽

10.1016/j.ejca.2014.01.031 ◽

2014 ◽

Vol 50 (8) ◽

pp. 1531-1540 ◽

Cited By ~ 16

Author(s):

Nils Kroeger ◽

David B. Seligson ◽

Sabina Signoretti ◽

Hong Yu ◽

Clara E. Magyar ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Poor Prognosis ◽

Clear Cell ◽

Clinicopathological Features ◽

Subcellular Localisation ◽

Phase I study of sorafenib and RAD001 for metastatic clear cell renal cell carcinoma

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.5109 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 5109-5109 ◽

Cited By ~ 8

Author(s):

J. E. Rosenberg ◽

V. K. Weinberg ◽

C. Claros ◽

C. Ryan ◽

A. M. Lin ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Phase I ◽

Cell Carcinoma ◽

Renal Cell ◽

Phase I Study ◽

Clear Cell ◽

Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial

British Journal of Cancer ◽

10.1038/bjc.2017.33 ◽

2017 ◽

Vol 116 (7) ◽

pp. 874-883 ◽

Cited By ~ 38

Author(s):

Roberto Pili ◽

Glenn Liu ◽

Sreenivasulu Chintala ◽

Hendrick Verheul ◽

Shabnam Rehman ◽

...

Keyword(s):

Clinical Trial ◽

Renal Cell Carcinoma ◽

Phase I ◽

Cell Carcinoma ◽

Histone Deacetylase ◽

Histone Deacetylase Inhibitor ◽

Renal Cell ◽

Clear Cell ◽

Deacetylase Inhibitor

Hypoxia-inducible factor (HIF)-prolyl hydroxylase 3 (PHD3) maintains high HIF2A mRNA levels in clear cell renal cell carcinoma

Journal of Biological Chemistry ◽

10.1074/jbc.ra118.004902 ◽

2019 ◽

Vol 294 (10) ◽

pp. 3760-3771 ◽

Cited By ~ 5

Author(s):

Petra Miikkulainen ◽

Heidi Högel ◽

Fatemeh Seyednasrollah ◽

Krista Rantanen ◽

Laura L. Elo ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Clear Cell ◽

Prolyl Hydroxylase ◽

Mrna Levels ◽

Hif Prolyl Hydroxylase

3-[(1S,2S,3R)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor for the Treatment of Clear Cell Renal Cell Carcinoma

Journal of Medicinal Chemistry ◽

10.1021/acs.jmedchem.9b00719 ◽

2019 ◽

Vol 62 (15) ◽

pp. 6876-6893 ◽

Cited By ~ 16

Author(s):

Rui Xu ◽

Keshi Wang ◽

James P. Rizzi ◽

Heli Huang ◽

Jonas A. Grina ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Clear Cell ◽

Identification of CDCP1 as a hypoxia-inducible factor 2α (HIF-2α) target gene that is associated with survival in clear cell renal cell carcinoma patients

Proceedings of the National Academy of Sciences ◽

10.1073/pnas.1222435110 ◽

2013 ◽

Vol 110 (9) ◽

pp. 3483-3488 ◽

Cited By ~ 38

Author(s):

Brooke M. Emerling ◽

Cyril H. Benes ◽

George Poulogiannis ◽

Eric L. Bell ◽

Kevin Courtney ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Target Gene ◽

Clear Cell ◽

656MO Phase II study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, plus cabozantinib for treatment of advanced clear cell renal cell carcinoma (ccRCC)

Annals of Oncology ◽

10.1016/j.annonc.2021.08.052 ◽

2021 ◽

Vol 32 ◽

pp. S681

Author(s):

D.F. McDermott ◽

T.K. Choueiri ◽

T.M. Bauer ◽

E. Arrowsmith ◽

A. Roy ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Renal Cell ◽

Clear Cell ◽

Phase Ii Study ◽